DUNDEE MEETING 7 bromophenol is formed from bromobenzene-3,4-oxide nonenzymically, the decrease in p-bromophenol formation may be used as an indirect measure of the decrease in the extracellular concentration of bromobenzene-3,4-oxide in the presence of the transferase. From these data, we found that only negligible amounts of the epoxide re-entered the cells; that is, kZ1 was negligible and that about 59% of the epoxide escaped the cells. This implies, however, that virtually all of the 3,4-dihydrobromobenzene-3,4-diol was formed extracellularly, because the formation of this metabolite was decreased by the addition of the GSH transferase B. Indeed, a plot of the rate of formation of the 3,4-di hydrobromobenzene-3,4-diol versus the rate of formation ofpbromophenol is consistent with the view that both are formed from the same kinetic compartment.
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From theoretical considerations, however, it is unlikely that the 3,4-dihydrobromobenzene-3,4-diol is formed nonenzymically. Instead, in the absence of enzymes, the arene oxide should decompose almost entirely to p-bromophenol. This would suggest, therefore, either that the theory is wrong or that the hepatocyte preparation became contaminated with microsomal membranes from cells destroyed during isolation.
From these studies it is clear that the arene oxides of bromobenzene are at least sufficiently long-lived within rat hepatocytes to belong to the category of intermediate-lived metabolites. Thus these metabolites may leave the cells in which they are formed and probably enter neighbouring cells. They also probably enter blood, where they may react with various components, including erythrocytes, and are swept downstream by the blood where they enter other hepatocytes or perhaps cells of other organs. Indeed, we have recently obtained indirect evidence that bromobenzene-3,4-oxide is present in systemic blood of rats receiving bromobenzene, which suggests the possibility that bromobenzene-3,4-oxide formed in liver may contribute to the toxicity of bromobenzene in extrahepatic organs (Lau et al., 1983 Nitroimidazoles have been widely used as therapeutic agents to treat bacterial and parasitic diseases in both humans and animals. Some nitroimidazoles have also been used as radiation sensitizers in the treatment of human cancer. Although the mechanisms by which nitroimidazoles exert their biological activities are still not clear, various studies have demonstrated the critical importance of the reduction of the nitro group in their cytotoxicity, mutagenicity and interaction with DNA (Lindmark & .Muller, 1976; Edwards, 1980; Voogd, 1981; Cantelli-Forti et al., 1983) . However, the reactive metabolites responsible for the biological activity of these nitroimidazoles have not been identified, As part of our programme designed to investigate the mechanism of drug residue formation, we have studied in detail the metabolic activation of a 5-nitroimidazole, ronidazole (1 -methyl-5-nitroimidazole-2-methanol carbamate). In this paper, we describe the mechanism involved in the formation in vitro of protein-bound adducts during the reduction of ronidazole. Evidence is presented that such protein adducts, unlike the parent 5-nitroimidazole, do not possess any mutagenic activity in the Ames test.
Metabolic activation
Various liver cellular fractions catalyse the metabolic activation of [14C]ronidazole to metabolite(s) bound to macromolecules. The covalent binding to proteins by [ ''C]ronidazole metabolite(s) is catalysed most efficiently by rat liver microsomal fractions and NADPH under anaerobic conditions (West et a/., 1982a). Inhibition studies suggest that cytochrome P-450 is involved in the metabolic activation of ronidazole (West et al., 19826) . Additional * To whom reprint requests should be addressed. studies have shown that purified NADPH-cytochrome P-450 reductase by itself can carry out this reaction. Stoichiometic measurements indicate that for every 20 molecules of ronidazole metabolized, only one molecule alkylates microsomal proteins (West et al., 1982a) .
Cellular targets
In the covalent binding system in vitro, reactive metabolite(s) of [14C]ronidazole preferentially binds to microsomal proteins; little or no binding to nucleic acids can be observed . The principal targets of protein alkylation are cysteine thiol groups, as shown by the inhibition of covalent binding by cysteine, but not by other amino acids (Miwa et a/., 1982). The cysteine thiol group appears to be the main functional group in bovine serum albumin that is susceptible to ronidazole attack. This conclusion is based on the finding that covalent binding of ronidazole to bovine serum albumin is strongly inhibited when the thio! group of the albumin is blocked as a methyl disulphide derivative, but restored when the blocking group is reductively removed (Miwa et al., 1982) . Further studies indicate that the covalent binding occurs with a variety of proteins and does not appear to be related to protein function. Thus bovine serum albumin is readily alkylated, and the radioautography of protein bands obtained from microsomal incubation shows that many proteins are alkylated, including cytochrome P-450 and NADPH+ytochrome P-450 reductase (West et al., 1982b) .
Protein-binding : structure-activity studies
In order to establish which part of the ronidazole molecule binds to the cysteine thiol groups of proteins, studies were conducted with ronidazole labelled with I4C at four different positions. Table 1 shows that ronidazole specifically labelled with 14C in the 4,5-ring, 1-N-methyl or 2-methylene positions gives virtually identical binding, suggesting that the imidazole nucleus of ronidazole is retained during covalent binding to proteins (Miwa ef al., 1982) . In contrast, the ~arbonyl-~~C-labelled ronidazole gives only 15% of the binding, indicating the loss of carbamoyl group during the reaction leading to covalent binding. Further VOl. 12 Table 1) show that the carbamate group is necessary for the generation of reactive metabolite(s) to achieve maximum covalent binding to proteins.
In addition to the important role of the carbamoyl group in protein binding, the C-4 position of ronidazole is also susceptible to nucleophilic attack during the reduction of the ni!ro group. For example, binding studies in vitro using [4-3H] ronidazole indicate that the ronidazole metabolite bound to protein retains very little radioactivity. In addition, studies on ronidazole using dithionite as the reducing agent and cysteine as the trapping nucleophile demonstrate that nucleophilic attack can occur at both the 2-methylene and 4-positions (Wislocki et al., 1983) .
On the basis of these structure-activity studies, it is concluded that the protein-bound products should have the following structural features: a reduced nitro group or its breakdown product at the 5-position, an intact imidazole nucleus, loss of the carbamoyl group, and alkylation by cysteine thiols at either the 4-position or the 2-methylene position, or both. However, it is still not known at which stage of nitro-reduction that reaction with cellular cysteine residue is initiated.
Mutagenicity : structure-activity sludies
Since 5-nitroimidazoles are generally mutagenic in the Ames test, it is important to examine what structural features of these compounds contribute to mutagenicity and to determine if the protein-bound adduct still retains mutagenic potential. On the basis of structure-activity studies on protein binding, three sites on the ronidazole molecules (namely the nitro group at C-5, the carbamoyl group at the 2-methylene position, and the C-4 position) were examined for their potential contributions to mutagenicity. As shown in Table 2 ,5-nitroimidazoles related to ronidazole but lacking the carbamoyl group (e.g. descarbamoyl ronidazole and dimetridazole) had decreased mutagenicity, confirming the biological importance of the carbamoyl group. The reduction of the mutagenic 5-nitroimidazole dimetridazole to 5-amino-l,2-dimethylimidazole renders this compound totally devoid of mutagenic activity even when the test was performed in the presence of liver S-9 fraction. Since the amino derivative of ronidazole is chemically unstable and cannot be synthesized, the acetylamino derivative of ronidazole was tested for mutagenicity. Again, this compound was found to be inactive, even though some aromatic amides have been shown to be activated to mutagenic compounds by enzymes present in the liver S-9 fraction. Finally, the monocysteine-ronidazole adduct (5-amino-4-S-cysteinyl-1,2-dimethylimidazole) is not mutagenic either in the absence or in the presence of S-9 fraction (Wislocki et al., 1983) .
From these results, it is clear that the presence of a nitro group at C-5 and the presence of the carbamoyl group at the 2-methylene position are essential for the mutagenicity of ronidazole. The reduction of the nitro group to the amine cesults in the total loss of mutagenic activity. Furthermore, once the amine is formed, it is not re-activated like those of other aromatic amines. In conclusion, the major ronidazole-protein adduct contains a reduced nitro function, has lost the carbamoyl group, and is alkylated by cysteine at the 2-methylene or 4-position. These structural alterations strongly suggest that the protein-bound adduct has lost all the mutagenic potential associated with the parent nitroimidazole. Similar structure-activity relationships in protein binding and mutagenicity suggest that the same reactive species is responsible for both biological events. It is now appreciated that a knowledge of the metabolism of anutrient chemicals in the body is frequently of importance in understanding their toxicity. The principal metabolic options of the carboxy group, conjugations with various amino acids and with glucuronic acid, were first discovered in the 19th Century (Williams, 1959) , and since then many studies have shown the versatility of these routes with respect to species distribution and substrate requirements (Caldwell et al., 1980; Caldwell, 1982) .
Xenobiotic acyl-coenzymes
The past few years have seen a considerable growth of our knowledge of the metabolic behaviour of the carboxy group, and a number of novel metabolic pathways have been discovered, which are listed in Table 1 . These pathways include various interactions with lipid-biosynthetic processes, the formation of sterol esters and the chiral inversion of the 2-arylpropionic acids (the 'profens', an important group of anti-inflammatory drugs). Detailed coverage of the reactions listed in Table 1 is to be found in the references cited.
It is clearly important to establish whether or not these novel metabolic reactions have any significance for the biological effects of carboxylic acids. A consideration of each is very strongly suggestive that there may exist important relationships between metabolism and effect. In the cases of the various interactions with lipid biosyntheses, involving both the hybrid fatty acids and hybrid triacylglycerols, their consequences may involve : (1) the establishment of long-lasting tissue residues of xenobiotics, which may or may not be mobilized from such stores; (2) disturbances of lipid biochemistry, particularly by disruptVOl. 12 ing the complex allosteric and feedback regulation of these processes; and (3) altered membrane function. Of the sterol esters described, that with cholesterol is readily and extensively deposited in rat hepatic lipid, and is resistant to removal from the liver (Fears et al., 1982) . The bile-salt esters are excreted to a great extent in the faeces, and may interfere with the enterohepatic circulation of endogenous bile salts (Quistad et al., 1982) . The chiral inversion of the asymmetric centre of the 2-arylpropionates involves the unidirectional conversion of their relatively inactive R ( -) isomers to the pharmacologically active S( + ) antipodes.
The consequences of this unique metabolic pathway are discussed in detail elsewhere (Hutt & Caldwell, 1983) , and include the need to define not only the structures of drugrelated materials in the body and excreta, but also their stereochemistry, with respect to compound, species and time, if relationships between disposition and effect are being sought.
In view of the likely importance of the various novel reactions of carboxylic acid metabolism, it becomes important to understand their mechanisms. Clearly, as forms without other metabolic change), e.g. ibuprofen
